Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHA:600671)

SHA:600671 Revenue

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd had revenue of 54.97M CNY in the quarter ending June 30, 2026, with 7.14% growth. This brings the company's total for the last twelve months to 207.51M, down -20.60% year-over-year. In the year 2025, Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd had annual revenue of 211.75M, down -2.55%. That makes Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd the 31,121st largest company in the world by revenue and 5,007th in China.

• Revenue (ttm): 207.51M
• Revenue Growth: -20.60%
• P/S Ratio: 10.77
• Revenue / Employee: 529.37K
• Employees: 392
• Market Cap: 2.24B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Health Care Products 90.99M 43.0%
• Circulating Commodities 50.35M 23.8%
• Active Pharmaceutical Ingredient (API) 30.30M 14.3%
• Chinese Patent Medicine 28.26M 13.3%
• Service Type 5.19M 2.5%
• Medical Instruments 3.79M 1.8%
• Chemical Medicine 1.84M 0.9%
• Other 979.71K 0.5%

Fiscal year ended Dec 31, 2025 See the full SHA:600671 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	211.75M	-5.54M	-2.55%
Dec 31, 2024	217.30M	95.52M	78.44%
Dec 31, 2023	121.78M	12.87M	11.82%
Dec 31, 2022	108.91M	-38.16M	-25.95%
Dec 31, 2021	147.07M	-59.56M	-28.82%

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 24, 2026

Data Sources Report a data error